HC Wainwright Comments on Centogene’s Q1 2024 Earnings (NASDAQ:CNTG)

Centogene (NASDAQ:CNTG – Get Rating) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Centogene in a report issued on Thursday, May 18th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.29) per share for the quarter. The consensus estimate for Centogene’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Centogene’s Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.23) EPS and FY2024 earnings at ($1.01) EPS.

Centogene Price Performance

NASDAQ CNTG opened at $0.87 on Monday. The stock’s fifty day moving average price is $0.80 and its 200 day moving average price is $0.92. Centogene has a 1 year low of $0.61 and a 1 year high of $3.18. The company has a market cap of $23.56 million, a price-to-earnings ratio of -0.37 and a beta of -0.91.

Hedge Funds Weigh In On Centogene

A hedge fund recently raised its stake in Centogene stock. Platinum Investment Management Ltd. raised its holdings in Centogene (NASDAQ:CNTG – Get Rating) by 4.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,377,150 shares of the company’s stock after purchasing an additional 106,000 shares during the quarter. Platinum Investment Management Ltd. owned 8.78% of Centogene worth $2,662,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.17% of the company’s stock.

About Centogene

(Get Rating)

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.